Drug Trial Radar · NCT05274893
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28
Planned (sponsor's estimate)
Start
Mar 31, 2022
Primary completion
Sep 30, 2022
Study completion Oct 30, 2022
Sponsor
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, pharmacokinetic comparison study of SYHX2011 and Abraxane® in patients with advanced breast cancers after single IV infusion.
Conditions
- Advanced Breast Cancer
Interventions
SYHX2011 and Abraxane®Drug
IV infusion, 260 mg/m\^2
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: From time zero up to 72 hours post-dose
- AUC0-tTime frame: From time zero up to 72 hours post-dose
- AUC0-∞Time frame: From time zero up to 72 hours post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.